Introduction
Matrix metalloproteinases (MMPs), a family of structurally related zinc-dependent endopeptidases, are key regulators of tissue reorganization that occurs in wound healing, inflammatory responses and malignancy (1) . In tumourigenesis, multiple and even opposite functions have been described for MMPs. They are involved in tumour initiation and progression, angiogenesis and activation of cytokines, but they can also exert tumour-inhibiting functions, e.g. by releasing antiangiogenic factors (2, 3) . In the complex tumour tissue, MMPs expressed by both tumour and stromal cells cooperate to promote tumour initiation and progression. There are .20 different human MMPs (1, 2) . Among them, the collagenase subfamily, with the fibroblast interstitial collagenase (MMP1), the neutrophil collagenase (MMP8), collagenase-3 (MMP13) and MMP14, play important roles for tumour progression and invasion due to their ability to degrade fibrillar collagens and components of the basement membrane (1, (4) (5) (6) (7) (8) (9) .
Whereas MMP8 has pro-tumourigenic and protective functions (10) , MMP1 and MMP13 are both associated with tumour growth and progression. Overexpression of human MMP1 has been demonstrated in a variety of advanced cancers like metastatic melanoma and colorectal, gastric, oesophageal, pancreatic and breast carcinoma (4, (11) (12) (13) (14) (15) (16) . In breast cancer, MMP1 is associated with a poor clinical outcome (17) and is now discussed as a potential predictive marker even for precancerous lesions (18) .
MMP13 is induced during invasion and metastasis of breast carcinomas, squamous cell carcinomas (SCCs), squamous cell carcinomas of the head and neck and melanomas (19) (20) (21) (22) (23) (24) (25) . In breast cancer, MMP13 expression correlates with progression to invasive carcinomas (26) . It is mainly attributed to stromal cells in close vicinity to tumour cells, supporting a crucial role of the stroma for tumour progression (24, 27) .
While these data clearly support the importance of MMP1 and MMP13 for the growth and progression of human cancer, the use of mouse models is indispensable to pinpoint their functional contribution. In mouse, the interstitial collagenase (MMP13) is homologous to human MMP13. However, the expression pattern of mouse MMP13 is comparable with human MMP1, strongly suggesting a functional homology between mouse MMP13 and both human MMP1 and MMP13 (5, 19, 28) . Accordingly, mouse MMP13 plays a role in physiological and pathological tissue remodelling, e.g. during bone development and the early phase of wound healing (28) (29) (30) (31) (32) . Mouse MMP13 is strongly upregulated in the stroma of breast cancer xenografts (33) and is induced in fibroblasts at the transition to invasion in a mouse mammary carcinoma model (34) . We previously demonstrated a strong expression of MMP13 in the stroma of highly malignant HaCaT-ras skin SCC xenografts (35, 36) and an almost complete downregulation in the non-invasive tumours that result from treatment with the angiogenesis inhibitor DC101 (35, 37) . This suggests a crucial function of MMP13 in driving tumour progression and invasive growth of skin SCCs.
In this study, we used Mmp13þ/þ and Mmp13À/À mice to analyze the functional role of MMP13 in growth, angiogenesis and invasion of early and advanced stages of skin carcinogenesis.
Material and methods
Transgenic animals Mmp13À/À mice were generated as described previously (32) and bred into a pure C57BL/6 background (.12 backcrosses). All animal experiments were performed in accordance with the governmental review committee on animal care (Regierungspräsidium Karlsruhe).
Cell lines PDVA cells were generated by in vitro 7,12-dimethylbenz(a)antracene treatment of B10LP mouse keratinocytes as described (38) . BDVII cells were established from 7,12-dimethylbenz(a)antracene-induced SCCs in C57BL/6 mice as described (39) . PDVA and BDVII cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum and tested negative for mycoplasma contamination as described (40) . Mouse embryonic fibroblasts (MEFs) were isolated from Mmp13þ/þ and Mmp13À/À littermate embryos and immortalized as described (41) .
Tumourigenicity assays in vivo: subcutaneous injection A total of 5 Â 10 6 BDVII cells were injected subcutaneously (s.c.) into both flanks of 5-to 6-week old Mmp13þ/þ and Mmp13À/À mice (four animals per group). Tumour size was measured weekly, and tumour volume was calculated as described (35) . The injection was repeated three times.
Surface transplantation assay
Tumour cells (BDVII) precultured on a collagen type I gel were transplanted onto the dorsal muscle fascia of 5-to 6-week old Mmp13þ/þ and Mmp13À/À mice as described (42) . For 5 weeks, four animals per group were killed and analyzed as described (35) . The transplantation was repeated twice.
Abbreviations: cDNA, complementary DNA; ECM, extracellular matrix; mRNA, messenger RNA; MEF, mouse embryonic fibroblast; MMP, matrix metalloproteinase; mMMP13, mouse matrix metalloproteinase-13; s.c., subcutaneous; SCC, squamous cell carcinoma; SMA, smooth muscle actin; VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor-2. Mmp13þ/þ or Mmp13À/À MEFs were prepared with native type I rat collagen (final concentration of 3 mg/ml) as described (43) . Tumour cells (8.5 Â 10 5 PDVA cells) were seeded on top of the collagen matrix. For 3 weeks, two cultures per week were harvested and processed for cryostat sectioning. Data shown are representatives of two independent experiments.
VEGF release studies
Dermal equivalents with irradiated (30 Gy) non-proliferating Mmp13þ/þ or Mmp13À/À MEFs (5 Â 10 5 cells/ml gel) were prepared as described (43) with 500 pg/ml, 2 ng/ml or 10 ng/ml recombinant human vascular endothelial growth factor (VEGF)-165 (R&D Systems, Wiesbaden, Germany) and cultured for 12 days. Conditioned medium was harvested every 72 h and VEGF concentrations were measured by enzyme-linked immunosorbent assay (human VEGF Quantikine ELISA Kit, R&D Systems). Each assay condition was tested in triplicate and repeated twice. 
Real-time polymerase chain reaction
Reverse transcription was performed as described (QIAGEN). For quantification of relative mRNA levels, cDNAs were amplified and real-time fluorimetric intensity was monitored according to the manufacturer's instructions using universal probe library-based technology and the LightCyclerÒ TaqManÒ Master (Roche Diagnostics, Mannheim, Germany). The following primers were used: mMMP13 forward: 5#-cagtctccgaggagaaactatgat-3# and mMMP13 reverse: 5#-ggactttgtcaaaaagagctcag-3# and for mouse hypoxanthine phosphoribosyl transferase forward: 5#-tgatagatccattcctatgactgtaga-3# and mouse hypoxanthine phosphoribosyl transferase reverse: 5#-aagacattctttccagttaaagttgag-3#. The mouse hypoxanthine phosphoribosyl transferase signal was determined in duplicates for each cDNA and used for normalization. All primer sets were assayed for quantitative PCR effectiveness. Relative transcription levels were determined as described (44) .
Antibodies
Primary antibodies were as follows: rat monoclonal antibody to mouse CD31 (BD PharMingen, Heidelberg, Germany), guinea pig pan-keratin anti-serum (Progen, Heidelberg, Germany), rabbit Ki-67 anti-serum (Acris, Bad Nauheim, Germany), rabbit collagen type IV anti-serum (Novotec, Lyon, France), biotinylated mouse monoclonal antibody to smooth muscle actin (SMA) (Progen), guinea-pig vimentin anti-serum (Progen), rat monoclonal antibody to mouse macrophages (ER-MP23; Acris), goat affinity purified antibody to murine MMP9 (R&D Systems), goat affinity purified antibody to murine VEGF (R&D Systems), goat affinity purified antibody to murine vascular endothelial growth factor receptor-2 (VEGFR-2) (R&D Systems). Sheep anti-MMP13 anti-serum (kind gift from G.Murphy, Cambridge, UK (45) . The specificity of the VEGF antibody was tested on HaCaT cells transfected with murine VEGF (data not shown). Secondary antibodies were obtained from Dianova, Hamburg, Germany.
Indirect immunofluorescence
Frozen sections were fixed in methanol and acetone and stained as described (43) . Cell nuclei were counterstained with 20 lg/ml Hoechst 33258/bisbenzimide (Sigma-Aldrich). Stained sections were examined with a Leica DM RBE fluorescence microscope (Leica GmbH, Wetzlar, Germany).
In situ hybridization In situ hybridization was performed as described (35) , using a digoxygeninlabelled probe for murine VEGF-164 (kindly provided by G.Breier, Institute of Pathology Technische Universität Dresden, Germany). Digoxigenin signals were detected by anti-digoxigenin alkaline phosphatase (Roche Diagnostics, Mannheim, Germany) and NBT-BCIP substrate reaction (Promega, Mannheim, Germany). Sections were counterstained against pan-keratin and collagen type IV and examined as described above. For better visualization of digoxigenin signals, colours were reassigned with the analySIS software (Soft Imaging Systems, Münster, Germany).
In situ zymography Proteolytic activity against collagen IV was demonstrated in unfixed cryostat sections using DQ collagen IV D-12052 (EnzChek; Molecular Probes, Invitrogen, Karlsruhe, Germany) as a substrate. Cryostat sections (7 lm) were incubated with 40 lg/ml DQ collagen IV in 1Â reaction buffer (0.5 M Tris-HCl, 1.5 M NaCl, 50 mM CaCl 2 , 2 mM sodium azide, pH 7.6) and counterstained by Hoechst 33258/bisbenzimide for 2 h at room temperature. After washing (3 Â 5 min in phosphate-buffered saline), sections were fixed in methanol and acetone and photographed with a Leica DM RBE fluorescence microscope (Leica GmbH).
Morphometric analysis
Quantification was performed for three areas of 1.5 mm 2 per section of four different animals from two independent transplantation series, using the analySIS software.
Statistics
Two-tailed Student's t-test was used for data analysis, with Ã P ,0.05 considered as statistically significant and ÃÃ P ,0.001 as highly significant.
Results

Stromal MMP13 is crucial for invasive growth of SCC cells
The role of stromal MMP13 in tumour growth of skin SCC was determined by s.c. injecting syngeneic BDVII SCC tumour cells (39) into Mmp13þ/þ and Mmp13À/À mice. In three independent experiments, BDVII SCC cells formed fast growing tumours in Mmp13þ/þ mice, reaching a mean size of $1.8 cm 3 after 4 weeks. In contrast, lack of MMP13 in Mmp13À/À mice restricted tumour growth to small nodules reaching sizes of only 0.13 cm 3 after 4 weeks ( Figure 1A ). To further determine the reasons for this difference in tumour growth, tumour sections were analyzed by immunohistology. Hoechst staining of cell nuclei combined with vascular endothelial cell staining by CD31 and keratin staining of the complete tumour mass demonstrated that tumour vascularization and invasion into the host stroma were dramatically impaired by the lack of stromal MMP13. In contrast to the well vascularized and highly invasive tumours of the Mmp13þ/þ mice, tumour nodules of Mmp13À/À animals consisted mostly of terminally differentiated cornified tissue with a small rim of vital tumour cells that was only marginally infiltrated by blood vessels ( Figure 1B) . Vital tumour cells were characterized by their double-positive staining for Hoechst (blue) and keratin (green), whereas no Hoechst stained nuclei were detected in the keratin-positive cornified areas consisting of terminally differentiated epithelial cells ( Figure 1B) . Analysis of cell proliferation by Ki67 staining confirmed that cell proliferation was restricted to the vital tumour cells containing Hoechst-positive nuclei and was absent in the strongly keratinized regions that lacked nuclear staining ( Figure 1C) . However, the proliferation rate in the vital tumour area was comparable between Mmp13þ/þ and Mmp13À/À mice ( Figure 1C ).
MMP13 is expressed in vascularized tumour areas and localized to fibroblasts
The differences in tumour vascularization indicated the involvement of stromal MMP13 in angiogenesis. We therefore analyzed the localization of MMP13 in the tumour stroma. In Mmp13þ/þ (Figure 2A ), but not in Mmp13À/À mice ( Figure 2B ), MMP13 protein was detected in the tumour invading stromal strands in close proximity to
CD31-positive blood vessels. MMP13 protein did not directly colocalize with the endothelial cells (Figure 2A) , and staining of tissue macrophages (ER-MP23 antibody) additionally excluded its colocalization with macrophages that were located at the outer stromal rim of the tumours far away from the vascularized MMP13-positive invasive areas ( Figure 2C ). In contrast, costaining of MMP13 with the myofibrobast marker SMA ( Figure 2D, counterstaining CD31) or the fibroblast marker vimentin ( Figure 2E , counterstaining keratin) revealed a close colocalization with the signals for MMP13. This suggested fibroblasts or myofibroblasts as main MMP13 producers and is in agreement with the previously described MMP13 expression in myofibroblasts at the tumour stroma border in the polyomavirus middle T breast carcinoma model (34) . Figure 3B , bar 1) yet, the expression was markedly upregulated in the presence of BDVII cells ( Figure 3A, panel 3 and Figure 3B, bar 3) .
In order to determine the direct influence of MMP13 expressing fibroblasts on growth and invasion of skin SCCs on collagen I, the substrate for MMP13, we established 3D organotypic cocultures of Mmp13þ/þ or Mmp13À/À MEFs with PDVA SCC cells. In contrast to the C57BL/6-derived BDVII SCC cells that were used for in vivo experiments and show a very extensive differentiation under in vitro growth conditions (data not shown), PDVA cells (derived from B10LP mice) proliferate well and form a multilayered three-dimensional epithelium with invasive capacities under these in vitro culture conditions. Haematoxylin and eosin staining demonstrated the presence of invasive tumour islets in the collagen gel ( Figure 3C , arrows) in 3-week-old cocultures with Mmp13þ/þ MEFs, associated with a reduced and interrupted collagen IV staining ( Figure 3D, arrows) . 
MMP13 mediates ongoing angiogenesis for invasive growth
In contrast, cocultures with Mmp13À/À MEFs showed a continuous collagen IV staining at the basement membrane zone and a more regular epithelial border ( Figure 3C and D) . However, proliferation rate of the PDVA cells was comparable in cocultures with Mmp13þ/þ and Mmp13À/À MEFs, as demonstrated by Ki67 staining ( Figure 3E ). In addition, a strong proteolytic activity against collagen IV was detected in the basement membrane zone of cocultures with Mmp13þ/þ fibroblasts ( Figure 3F -H, left panels, arrows mark the areas with proteolytic activity), whereas no proteolytic activity against collagen IV was detected in the basement membrane zone of cocultures with Mmp13À/À MEFs ( Figure 3F -H, right panels, arrowheads show the lack of collagenolytic activity). These data support a role of fibroblast-derived MMP13 for the invasive growth of malignant SCC cells.
Lack of stromal MMP13 strongly impairs tumour vascularization
The only moderate invasive growth behaviour of the SCC cells in the organotypic cocultures suggested a more complex function of MMP13 beyond simple collagen degradation. To determine the specific contribution of MMP13 to initial tumour growth, angiogenesis and invasion in the complex tissue environment in vivo, BDVII SCC cells were transplanted as preformed epithelia on collagen type I gels onto the muscle fascia of Mmp13þ/þ and Mmp13À/À mice. In this model, the collagen gel delays the contact between tumour and stroma but allows the interaction via diffusible factors, thereby enabling the detailed characterization and temporal analysis of stromal activation, cellular recruitment, angiogenesis and invasion (42) .
The recruitment of SMA-positive fibroblasts was similar in transplants of Mmp13þ/þ and Mmp13À/À animals during the whole observation period (data not shown). In contrast, the angiogenic response and initial tumour cell infiltration into the stroma were only comparable between early transplants of Mmp13þ/þ and Mmp13À/À mice, as analyzed by immunostaining to CD31 (endothelial cells), pan-keratin (tumour tissue) and Hoechst (nuclei of vital tumour cells). Significant differences became obvious starting from week 3 post-transplantation. In transplants of Mmp13þ/þ animals, angiogenesis and tumour cell invasion were maintained, resulting in large invasive and highly vascularized tumours at week 4-5 ( Figure 4A ). In contrast, vascularization of the tumour tissue was dramatically impaired in the absence of host MMP13, leading to a mostly avascular cornified tumour tissue at week 4-5 and to an almost complete abrogation of tumour cell invasion ( Figure 4A ). Quantification confirmed an equal vessel density in the invasive areas 2 weeks post-transplantation ( Figure 4B ) but a significantly reduced vascular density in the tumour tissue starting from week 3 in transplants of Mmp13À/À animals compared with transplants of Mmp13þ/þ mice ( Figure 4B ). These data suggest a crucial contribution of MMP13 to the maintenance of angiogenesis and tumour invasion.
MMP13 induction is associated with a strong VEGF protein increase in the angiogenic areas
To further pinpoint the role of MMP13 in angiogenesis and invasion, we analyzed the kinetics of MMP13 expression in the surface transplants of wild-type animals by immunostaining with antibodies to MMP13, CD31 (vascular endothelial cells) and pan-keratin (tumour tissue). While MMP13 protein was absent in transplants of wild-type animals 2 weeks post-transplantation ( Figure 5A) , it appeared at week 3 and was strongly detected in the stromal strands at week 4 and 5 after transplantation concomitantly with the establishment of a highly vascularized and invasive tumour phenotype ( Figure 5A ). In addition, MMP13 expression coincided with a strong increase in VEGF protein in the invasive areas around blood vessels starting from week 3 ( Figure 5B ), whereas VEGF was only very weakly detected at the Figure 6A, panels 1 and 2) . In tumours of Mmp13À/À mice, the almost complete lack of VEGF protein staining coincided with a strong decrease in VEGFR-2 staining ( Figure 6A, panels 3 and 4) . Despite this striking difference in detectable VEGF protein, we found no difference in VEGF mRNA expression, as determined by in situ hybridization with a probe specific for murine VEGF-164 ( Figure 6B and C) . VEGF mRNA was strongly expressed by tumour and stromal cells in surface transplants of both, Mmp13þ/þ and Mmp13À/À animals at early and late time points.
One possible explanation for this discrepancy in mRNA detection and protein staining might be sequestration of VEGF protein in the extracellular matrix (ECM) in the absence of MMP13, thus 
blue). (F-H)
In situ zymography for proteolytic activity against collagen IV in organotypic cocultures after 7, 14 and 21 days of culture with Mmp13þ/þ MEFs (left panels, arrows mark the areas with collagenolytic activity) and in organotypic cocultures with Mmp13À/À MEFs (right panels, arrowheads show respective areas without collagenolytic activity), nuclei are counterstained by Hoechst (blue); Bars 100 lm (C-H).
MMP13 mediates ongoing angiogenesis for invasive growth preventing sufficient antibody binding for detection. To determine this, we generated dermal equivalents consisting of Mmpþ/þ and Mmp13À/À MEFs embedded in a collagen type I gel that contained different concentrations of human VEGF-165 (0.5-10 ng/ml). The amount of human VEGF released was measured by a speciesspecific enzyme-linked immunosorbent assay in conditioned media over a period of 12 days. The retention of VEGF in the gel was clearly enhanced in gels containing fibroblasts as compared to gels without fibroblasts (data not shown), suggesting the presence of additional ECM components that had been produced by fibroblasts and were able to bind VEGF. Independently of the initial concentration in the gel, VEGF concentrations released into the conditioned media of gels containing Mmp13þ/þ MEFs were higher than for gels with Mmp13À/À MEFs ( Figure 6D , representative data shown for 500 pg/ml at day 6). This also held true for gels containing the fibroblasts in a fibronectin-and heparin-enriched collagen gel (data not shown). These results strongly indicate that MMP13 mediates the release of VEGF from dermal equivalents with wildtype fibroblasts.
Discussion
Our study demonstrates a crucial contribution of MMP13 to tumour progression of skin SCCs by maintaining angiogenesis and tumour cell invasion and thus augments the recently discovered novel roles of MMPs in tumourigenesis. Besides directly facilitating tumour cell migration and invasion through ECM degradation, MMPs have been demonstrated to exert indirect pro-tumourigenic functions by releasing growth factors from the ECM (1, 46) . Among them are the transforming growth factor beta or the basic fibroblast growth factor with a relatively broad range of action. Additionally, recent studies have demonstrated a critical role for MMP9 in mediating the release of the key angiogenic factor VEGF from the ECM, thereby stimulating angiogenesis and the initial onset of tumour growth (47) . Using Mmp13þ/þ and Mmp13À/À mice, we now demonstrate a similar crucial function for MMP13 in driving tumour vascularization and invasion by promoting the persistent release of VEGF from the ECM at sites of invasion. While the s.c. injection of SCC cells in Mmp13þ/þ mice induced the formation of highly vascularized invasive tumours, the tumours formed in Mmp13À/À mice were small and (48) . However, in contrast to the endothelial MMP13 expression observed in melanoma, MMP13 did clearly not colocalize with endothelial cells in tumours of wild-type mice in our skin SCC-model, although it was detected in the invasive areas nearby blood vessels. Colocalization studies for macrophages that were identified as MMP13 producers in the chorioallantoic membrane assay and in fibrotic lung tissue (49,50) also excluded macrophages as cellular source of host MMP13, since they were located at the outer stromal rim far away from the invasive areas. In contrast, MMP13 protein was found in close vicinity to SMA-positive cells and partially colocalized with vimentin-positive cells, strongly suggesting stromal fibroblasts as the main source of MMP13. Expression of MMP13 was described previously for skin fibroblasts (51) and breast cancer cell-associated myofibroblasts (34) . The hypothesis of stromal fibroblasts as source of MMP13 was substantiated by in vitro experiments, showing basal MMP13 expression in fibroblasts isolated from Mmp13þ/þ embryos that was strongly upregulated in coculture with SCC cells. More importantly, in three-dimensional organotypic cocultures Mmp13þ/þ fibroblasts but not Mmp13À/À fibroblasts supported the invasive growth of SCC cells into the collagen gel and the degradation of the basement membrane component collagen IV. Although MMP13 is mostly described as protease targeting interstitial collagens, it has been demonstrated to effectively cleave also collagen IV (52) . In agreement with this, we detected a strong proteolytic activity against collagen IV in the basement membrane zone of organotypic cocultures with Mmp13þ/þ fibroblasts, whereas no activity was observed in cocultures with Mmp13À/À fibroblasts. However, the only moderately invasive growth behaviour of the SCC cells in the 3D organotypic cocultures compared to the s.c. tumours suggested that MMP13 exerts additional invasion supporting functions beyond simply degrading interstitial collagens and collagen IV. This became obvious by analyzing tumour growth, invasion and angiogenesis in the surface transplantation model, where the tumour cells are initially separated from the host tissue by a collagen type I gel. While MMP13 was clearly needed for the establishment of an invasive tumour phenotype, kinetic analyses revealed that host MMP13 was not responsible for initial tumour growth and the early stromal activation. During the first 2 weeks after transplantation, MMP13 expression was absent and initial angiogenesis and tumour cell invasion into the stromal compartment were comparable in 
MMP13 mediates ongoing angiogenesis for invasive growth
Mmp13þ/þ and Mmp13À/À animals. MMP13 expression was induced in the wild-type mice at week 3 after transplantation coinciding with the maintenance of angiogenesis and expression of the interstitial collagenase resulted in highly invasive and vascularized tumour transplants comparable with the s.c. tumours. In contrast, angiogenesis and tumour invasion were reduced in the absence of host MMP13, leading to a mostly avascular cornified tumour tissue like in the s.c. tumours. These observations strongly suggested a crucial role of MMP13 in the maintenance of angiogenesis at the invasive tumour stage. In support of this hypothesis, MMP13 induction in wild-type animals coincided with a strong increase in VEGF protein staining within these invasive areas, whereas VEGF protein was only weakly detected at the tumour stroma border in the knockout transplants. In addition, immunostaining on parallel cryosections from s.c. tumours of wild-type animals demonstrated that VEGF protein was strongly enriched around blood vessels and colocalized with the VEGFR-2, indicating the presence of active VEGF bound to its receptor. In contrast, VEGF protein was almost absent and staining for VEGFR-2 was strongly decreased in tumours of Mmp13À/À mice. These observations suggested that MMP13 is involved in ongoing angiogenesis via VEGF-mediated effects. However, the differences in protein staining were not based on different VEGF expression levels, since we detected a strong expression of VEGF mRNA in tumour and stromal cells of both, Mmp13þ/þ and Mmp13À/À animals. The drastic reduction in VEGF protein staining despite ongoing mRNA expression in Mmp13À/À animals could be due to sequestration of VEGF in the absence of host MMP13, thus preventing sufficient antibody binding for detection. In Mmp13þ/þ animals, MMP13 might release VEGF from the ECM, thereby allowing its binding to the VEGFR-2 on endothelial cells and thus promoting angiogenesis, as it was described for MMP9 in early tumourigenesis of the Rip1Tag2 model (47) . This hypothesis was substantiated in vitro by generating dermal equivalents of Mmp13þ/þ or Mmp13À/À fibroblasts embedded in a collagen type I gel containing human VEGF. The amount of VEGF that was released to the medium was clearly enhanced in the dermal equivalents with Mmp13þ/þ fibroblasts. Thus, we postulate that MMP13 promotes the maintenance of angiogenesis in wild-type animals by releasing ECM-bound VEGF. While lack of MMP13 did not affect angiogenesis and tumour growth in a polyoma middle T antigen mammary carcinoma model possibly due to the compensatory effects of other proteolytic enzymes (34) , angiogenesis promoting functions of MMP13 were described previously in the CAM assay (50) . Indirect evidence for VEGF and angiogenesis regulating functions of MMP13 also comes from detailed analyses of Mmp13À/À embryos which showed delayed endochondral ossification and a reduced vascularization of the primary ossification center at day 15.5 (29) . Again, VEGF mRNA expression in the ossification centre was abundant, suggesting the reduced availability of VEGF protein as potential reason for this phenotype. In further agreement with a VEGF-mediated role of MMP13 in angiogenesis, JunB-deficient endothelial cells that show strongly decreased levels of endogenous MMP13 failed to form capillary-like networks in matrigel (53) . The detailed mechanism by which MMP13 releases VEGF from the ECM, e.g. by degradation of VEGF-binding fibronectin is subject of further investigation (52, 54) . In summary, our data strongly suggest a novel role of MMP13 in promoting tumour malignancy and invasion by maintaining and enhancing angiogenesis through the release of VEGF from the tumour ECM. Our studies clearly strengthen the crucial contribution of the tumour microenvironment to the growth of malignant cells and emphasize the importance of analyzing the role of specific MMPs in tumour initiation and progression to identify potentially successful therapeutic targets.
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